Nemes Rush Group LLC Purchases 4,158 Shares of Gilead Sciences, Inc. $GILD

Nemes Rush Group LLC increased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 18.6% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 26,508 shares of the biopharmaceutical company’s stock after buying an additional 4,158 shares during the quarter. Nemes Rush Group LLC’s holdings in Gilead Sciences were worth $2,942,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. Norges Bank bought a new position in shares of Gilead Sciences during the second quarter worth about $2,150,268,000. Ameriprise Financial Inc. lifted its stake in shares of Gilead Sciences by 397.6% in the second quarter. Ameriprise Financial Inc. now owns 6,748,403 shares of the biopharmaceutical company’s stock worth $748,147,000 after acquiring an additional 5,392,191 shares during the period. Invesco Ltd. boosted its holdings in Gilead Sciences by 33.5% in the second quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock valued at $1,499,098,000 after acquiring an additional 3,394,330 shares during the last quarter. Assenagon Asset Management S.A. boosted its holdings in Gilead Sciences by 164.4% in the third quarter. Assenagon Asset Management S.A. now owns 3,489,062 shares of the biopharmaceutical company’s stock valued at $387,286,000 after acquiring an additional 2,169,266 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in Gilead Sciences by 1.6% during the 2nd quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company’s stock valued at $13,233,912,000 after purchasing an additional 1,893,401 shares during the period. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Jefferies initiated coverage on Gilead with a Buy and $180 price target (≈21% upside vs. recent levels), which can attract fresh demand and lift sentiment among institutional investors. Jefferies coverage
• Positive Sentiment: Short interest fell ~15.7% in February to ~18.45M shares (1.5% of float), lowering potential short-squeeze dynamics and reducing downward pressure from bearish positioning; days-to-cover sits near 2.7 days based on average volume. (Data reported 3/10/2026)
• Positive Sentiment: Gilead agreed to acquire Arcellx (ACLX) for up to $7.8B — a deal meant to broaden Gilead’s cancer/ cell therapy pipeline; the acquisition signals management’s push into higher-growth oncology assets and helps explain investor buying. Gilead to acquire Arcellx
• Positive Sentiment: Market research (DelveInsight) forecasts strong expansion in the CD19 inhibitors market (oncology & autoimmune indications), supporting a favorable long-term backdrop for companies building CAR-T/ cell‑therapy franchises like Gilead. CD19 market outlook
• Neutral Sentiment: Gilead presented at the Leerink Global Healthcare Conference — the transcript may offer management color on pipeline timing, margins and M&A rationale but typically affects stock movement only after materially new guidance or data. Leerink presentation transcript
• Neutral Sentiment: Market write-ups (Yahoo/Zacks/247WallSt) noted Gilead’s outperformance and recent analyst coverage changes; these summaries reflect current momentum but are second‑order drivers unless paired with new data or ratings revisions. Market coverage

Insider Activity at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $154.43, for a total transaction of $463,290.00. Following the transaction, the chief financial officer owned 167,779 shares of the company’s stock, valued at $25,910,110.97. This represents a 1.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $123.50, for a total value of $617,500.00. Following the completion of the sale, the director directly owned 8,920 shares of the company’s stock, valued at $1,101,620. The trade was a 35.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 309,280 shares of company stock worth $43,935,470 over the last three months. 0.27% of the stock is currently owned by company insiders.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $148.56 on Wednesday. The company has a market cap of $184.43 billion, a price-to-earnings ratio of 21.94, a price-to-earnings-growth ratio of 1.92 and a beta of 0.37. Gilead Sciences, Inc. has a 52 week low of $93.37 and a 52 week high of $157.29. The company has a quick ratio of 1.40, a current ratio of 1.55 and a debt-to-equity ratio of 0.98. The firm has a 50 day moving average of $139.23 and a 200-day moving average of $126.30.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.83 by $0.03. The company had revenue of $7.93 billion for the quarter, compared to the consensus estimate of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. Gilead Sciences’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, equities analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Stockholders of record on Friday, March 13th will be issued a dividend of $0.82 per share. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 annualized dividend and a dividend yield of 2.2%. The ex-dividend date is Friday, March 13th. Gilead Sciences’s dividend payout ratio (DPR) is currently 46.68%.

Analysts Set New Price Targets

GILD has been the subject of several analyst reports. Weiss Ratings restated a “buy (b)” rating on shares of Gilead Sciences in a report on Thursday, January 22nd. Wells Fargo & Company upped their price objective on shares of Gilead Sciences from $150.00 to $165.00 and gave the company an “overweight” rating in a research note on Wednesday, February 11th. Leerink Partners increased their price objective on shares of Gilead Sciences from $146.00 to $148.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 11th. Wolfe Research lifted their target price on shares of Gilead Sciences from $155.00 to $170.00 and gave the stock an “outperform” rating in a research note on Thursday, February 12th. Finally, UBS Group boosted their target price on shares of Gilead Sciences from $145.00 to $155.00 and gave the company a “buy” rating in a report on Monday, January 26th. Twenty-four research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and an average price target of $157.62.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.